A Phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia

Administered By

Awarded By

Contributors

Start/End

  • April 1, 2015 - November 1, 2022